Immune checkpoint therapy in liver cancer

Targeting Epigenetics in Cancer

(2018) Richard L. Bennett et al.   Annual Review of Pharmacology and Toxicology

Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies

(2018) Shetal A. Patel et al.   IMMUNITY

The signature of liver cancer in immune cells DNA methylation

(2018) Yonghong Zhang et al.   Clinical Epigenetics

Clinical Grade Regulatory CD4+ T Cells (Tregs): Moving Toward Cellular-Based Immunomodulatory Therapies

(2018) Richard Duggleby et al.   Frontiers in Immunology

Progressive epigenetic dysregulation in neuroendocrine tumour liver metastases

(2017) Anna Karpathakis et al.   ENDOCRINE-RELATED CANCER

Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas

(2017) Guoying Zhou et al.   GASTROENTEROLOGY

Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy

(2017) Leslie S. Kean et al.   IMMUNOLOGICAL REVIEWS

Epigenetic regulation of immune checkpoints: another target for cancer immunotherapy?

(2017) Mahmoud A Ali et al.   Immunotherapy

Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study

(2017) Patrick A. Ott et al.   JOURNAL OF CLINICAL ONCOLOGY

STAT3-blocked whole-cell hepatoma vaccine induces cellular and humoral immune response against HCC

(2017) Qiuju Han et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Current progress in immunotherapy of hepatocellular carcinoma

(2017) Martin F. Sprinzl et al.   JOURNAL OF HEPATOLOGY

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

(2017) Anthony B El-Khoueiry et al.   LANCET

Epigenetics and immunotherapy: The current state of play

(2017) Jennifer Dunn et al.   MOLECULAR IMMUNOLOGY

Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma

(2017) Jianhua Liu et al.   ONCOLOGY REPORTS

The PD-1/PD-L1 axis may be aberrantly activated in occupational cholangiocarcinoma

(2017) Yasunori Sato et al.   PATHOLOGY INTERNATIONAL

Tumor-derived CD4+CD25+regulatory T cells inhibit dendritic cells function by CTLA-4

(2017) Xin Chen et al.   PATHOLOGY RESEARCH AND PRACTICE

Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden

(2017) Meredith L. Stone et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab

(2017) Udupi A. Ramagopal et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Positive Expression of Programmed Death Ligand 1 in Peritumoral Liver Tissue is Associated with Poor Survival after Curative Resection of Hepatocellular Carcinoma

(2017) Xiaomeng Dai et al.   Translational Oncology

A competing endogenous RNA network identifies novel mRNA, miRNA and lncRNA markers for the prognosis of diabetic pancreatic cancer

(2017) Kanyu Yao et al.   TUMOR BIOLOGY

The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy

(2017) Daniel Zingg et al.   Cell Reports

Epigenetic modifications of the immune-checkpoint genes CTLA4 and PDCD1 in non-small cell lung cancer results in increased expression

(2017) Sebastian Marwitz et al.   Clinical Epigenetics

Epidemiology and risk factors: intrahepatic cholangiocarcinoma

(2017) Amar Gupta et al.   HEPATOBILIARY SURGERY AND NUTRITION

CTLA-4 and PD-1 Pathways

(2016) Elizabeth I. Buchbinder et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma

(2016) Faiz Gani et al.   ANNALS OF SURGICAL ONCOLOGY

Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade

(2016) Haidong Tang et al.   CANCER CELL

Combining Epigenetic and Immunotherapy to Combat Cancer

(2016) Katherine B. Chiappinelli et al.   CANCER RESEARCH

Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features

(2016) Julien Calderaro et al.   HEPATOLOGY

Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation

(2016) Ana C. Anderson et al.   IMMUNITY

CXCL10/CXCR3 signaling mobilized-regulatory T cells promote liver tumor recurrence after transplantation

(2016) Chang Xian Li et al.   JOURNAL OF HEPATOLOGY

Immune checkpoint proteins PD-1 and TIM-3 are both highly expressed in liver tissues and correlate with their gene polymorphisms in patients with HBV-related hepatocellular carcinoma

(2016) Zhu Li et al.   MEDICINE

Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise

(2016) Supriya K. Saha et al.   ONCOLOGIST

CXCL12 expression and PD-L1 expression serve as prognostic biomarkers in HCC and are induced by hypoxia

(2016) Alexander Semaan et al.   VIRCHOWS ARCHIV

Epigenetic epidemiology as a tool to understand the role of immunity in chronic disease

(2016) Heather H Nelson et al.   Epigenomics

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

(2016) Shohei Koyama et al.   Nature Communications

Immune Checkpoint Blockade in Hepatocellular Carcinoma: 2017 Update

(2016) Masatoshi Kudo   Liver Cancer

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

Molecular Pathways: At the Crossroads of Cancer Epigenetics and Immunotherapy

(2015) M. Maio et al.   CLINICAL CANCER RESEARCH

PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma

(2015) F. Sabbatino et al.   CLINICAL CANCER RESEARCH

Tim-3 fosters HCC development by enhancing TGF-β-mediated alternative activation of macrophages

(2015) Wenjiang Yan et al.   GUT

Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy

(2015) Dongjun Peng et al.   NATURE

MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints

(2015) Jun Wei et al.   NEURO-ONCOLOGY

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy

(2015) W. Peng et al.   Cancer Discovery

Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors

(2015) D. S. Thommen et al.   Cancer Immunology Research

HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade

(2015) D. M. Woods et al.   Cancer Immunology Research

Impaired Function of CD4+ T Follicular Helper (Tfh) Cells Associated with Hepatocellular Carcinoma Progression

(2015) Yiqiong Jia et al.   PLoS One

Alterations of immune response of non-small cell lung cancer with Azacytidine

(2015) John Wrangle et al.   Oncotarget

Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies

(2014) G. K. Philips et al.   INTERNATIONAL IMMUNOLOGY

Epigenetic drugs as immunomodulators for combination therapies in solid tumors

(2014) Luca Sigalotti et al.   PHARMACOLOGY & THERAPEUTICS

Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression

(2014) Limo Chen et al.   Nature Communications

Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer

(2013) Julie E. Bauman et al.   CANCER

Locoregional therapy for cholangiocarcinoma

(2013) Jan B. Kuhlmann et al.   CURRENT OPINION IN GASTROENTEROLOGY

Dendritic Cell-Based Immunotherapy Targeting Synthesized Peptides for Advanced Biliary Tract Cancer

(2013) Masanori Kobayashi et al.   JOURNAL OF GASTROINTESTINAL SURGERY

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents

(2013) H Yang et al.   LEUKEMIA

SAHA/Vorinostat induces the expression of the CD137 receptor/ligand system and enhances apoptosis mediated by soluble CD137 receptor in a human breast cancer cell line

(2012) DANIELA BELLAROSA et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

T-cell suppression mediated by regulatory T cells infiltrating hepatic tumors can be overcome by GITRL treatment

(2012) Alexander Pedroza-Gonzalez et al.   OncoImmunology

Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma

(2011) Eishiro Mizukoshi et al.   HEPATOLOGY

Management of hepatocellular carcinoma: An update

(2011) Jordi Bruix et al.   HEPATOLOGY

Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice

(2011) W. Joost Lesterhuis et al.   JOURNAL OF CLINICAL INVESTIGATION

Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses

(2009) W M Liu et al.   BRITISH JOURNAL OF CANCER

Kupffer Cell Suppression of CD8+ T Cells in Human Hepatocellular Carcinoma Is Mediated by B7-H1/Programmed Death-1 Interactions

(2009) K. Wu et al.   CANCER RESEARCH

Interaction of B7-H1 on intrahepatic cholangiocarcinoma cells with PD-1 on tumor-infiltrating T cells as a mechanism of immune evasion

(2009) Yufu Ye et al.   JOURNAL OF SURGICAL ONCOLOGY

Interaction of human PD-L1 and B7-1

(2008) Manish J. Butte et al.   MOLECULAR IMMUNOLOGY

Epigenetics in Cancer

(2008) Manel Esteller   NEW ENGLAND JOURNAL OF MEDICINE

CTLA-4 Control over Foxp3+ Regulatory T Cell Function

(2008) K. Wing et al.   SCIENCE